Skip to content

Revenue at other companies

Henry Schein logo
Henry ScheinHSIC
$3.37B+6.3%
CSX logo
CSXCSX
$3.48B+1.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$246.09M+87.0%
SBA Communications logo
SBA CommunicationsSBAC
$47.29M-1.6%
Loar Holdings logo
Loar HoldingsLOAR
$9.7M+48.1%
Armstrong World Industries logo
Armstrong World IndustriesAWI
$382.9M+12.8%

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s revenue?
ImmunityBio, Inc. (IBRX) reported revenue of $44.21M in Q1 2026.
How has ImmunityBio, Inc.'s revenue changed year-over-year?
ImmunityBio, Inc.'s revenue increased by 167.6% year-over-year, from $16.52M to $44.21M.
What is the long-term trend for ImmunityBio, Inc.'s revenue?
Over 3 years (2022 to 2025), ImmunityBio, Inc.'s revenue has grown at a 678.6% compound annual growth rate (CAGR), from $240K to $113.29M.